Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment efficacy was one of the secondary endpoints. In patients with CNS metastases, the concentration in the cerebrospinal fluid was also measured. Forty-one patients were enrolled. The frequency of AEs was highest for rash, followed by anorexia and thrombocytopenia. Thirty-eight cases provided measurements for P1. The median plasma concentration of osimertinib was 227 ng/mL, and that of AZ5104 was 16.5 ng/mL. The mean CNS penetration rate of two cases was 3.8%. The P1 in the group with anorexia was significantly higher than that in the group without anorexia (385.0 ng/mL vs. 231.5 ng/mL, p = 0.009). Divided into quartiles by P1 trough level, Q2 + Q3 (164–338 ng/mL) had longer PFS, while Q1 and Q4 had shorter PFS. An appropriate plasma level of osimertinib may avoid some adverse events and induce long PFS. Further large-scale trials are warranted.
We evaluated the area under the plasma concentration–time curve (AUC) of afatinib required to avoid the onset of grade 2 or higher diarrhea. The C0 and AUC0–24 of afatinib were significant higher in patients with grade 2 diarrhea than in those with grade 0–1 diarrhea. The areas under the receiver operator curves were 0.795 with the highest sensitivity (89%) and specificity (74%) at an AUC0–24 threshold of 823.5 ng·h/mL, and 0.754 with the highest sensitivity (89%) and specificity (74%) at a C0 threshold of 28.5 ng/mL. In Kaplan–Meier analysis based on these cut-off AUC0–24 and C0 values, the median time to the incidence of grade 2 diarrhea was 16 days. The predicted AUC0–24 of afatinib from the single point of C6 showed the highest correlation with the measured AUC0–24 (r2 = 0.840); however, a significant correlation between the AUC0–24 and C0 was also observed (r2 = 0.761). C0 could be used as a marker of therapeutic drug monitoring because afatinib C0 was related to AUC0–24. Therefore, afatinib C0 should be monitored on day 8 after beginning therapy, and the daily dose of afatinib should be adjusted as an index with a cut-off value of 28.5 ng/mL.
13 May 2020 in Journal of Clinical Pharmacy and Therapeutics
Introduction: Erlotinib (ERL) is metabolized primarily by cytochrome P450 (CYP) 3A4. We report a case of non–small cell lung cancer in which plasma ERL concentrations increased following coadministration of itraconazole (ITCZ). Case Presentation: In this patient, a 67‐year‐old man receiving ERL 150 mg/day, the trough plasma concentration ( C0 ) of ERL and its major metabolite, O‐desmethyl ERL (OSI‐420), increased following coadministration of ITCZ. The total clearance of ERL at steady state was 6.1 L/h. The mean C0 of ERL and OSI‐420 were 437 and 47.1 ng/mL, respectively, and the C0 ratio of OSI‐420/ERL was 0.108. With coadministration of oral ITCZ (200 mg/day capsule), the mean C0 of ERL and OSI‐420 increased to 1124 and 166 ng/mL, respectively, and the mean C0 ratio of OSI‐420/ERL increased to 0.147. The mean C0 of ITCZ and the sum of ITCZ and the active metabolite hydroxyitraconazole (OH‐ITCZ) were 109 and 271 ng/mL, respectively. The mean C0 of ERL increased approximately 2.5‐fold. Conclusion: Even at the relatively lower C0 of ITCZ (compared with the recommended target value), ITCZ coadministration increased the C0 of ERL. In patients with a sufficient ERL C0 of more than 500 ng/mL prior to ITCZ coadministration or patients exhibiting adequate absorption of oral ITCZ, the risk of ERL‐related adverse events with ITCZ coadministration may increase due to further elevation of the ERL C0 . Therefore, when ERL is coadministered with ITCZ, careful monitoring for adverse effects and appropriate dose adjustments are required, considering potential changes in ERL concentrations. Management using the C0 of ERL and ITCZ may be necessary.
18 May 2026 in Journal of Pharmaceutical Health Care and Sciences
Background: Voriconazole (VRCZ) is an effective treatment for pulmonary aspergillosis. Active infectious disease leads to a reduction in cytochrome P450 activity, resulting in increased VRCZ concentrations. However, the impact of VRCZ dose reduction during the severe inflammatory state on VRCZ concentrations after the resolution of inflammation is not yet fully understood. Here, we report the time-course changes in VRCZ blood concentrations after inflammation in a patient with invasive pulmonary aspergillosis. Case presentation: A man in his 60s receiving oral VRCZ tablets at 400 mg/day for invasive pulmonary aspergillosis developed marked inflammation due to bacterial pneumonia and influenza virus infection. C-reactive protein (CRP) levels increased to a peak of 35.54 mg/dL, with a concomitant elevation in the VRCZ trough concentration to 4.7 µg/mL. Following dose reduction to VRCZ 300 mg/day, the trough concentration decreased to 1.1 µg/mL on day 11 after dose reduction, while CRP declined to 4.78 mg/dL after antibiotic therapy. VRCZ was continued at the same dose. However, four weeks after CRP levels had stabilized, the VRCZ concentration decreased to 0.6 µg/mL. After re-escalation of VRCZ to 400 mg/day, the trough concentration returned to the effective therapeutic range of 1.1 µg/mL. Conclusions: After infection is controlled, VRCZ concentrations may decrease to levels below the therapeutic range. Following VRCZ dose reduction during a high inflammatory state, reassessment of trough concentrations after improvement of inflammation may be useful to prevent excessive decreases in VRCZ concentrations.